The latest round of the Horizon 2020 SME Instrument has seen the successful funding of a Luxembourgish SME, Braingineering Technologies, which has been positively evaluated for a Phase 1 project.

SMEs (Small and Medium-sized Enterprises) that are EU-based or established in a country associated with Horizon 2020 can get EU funding and support for “breakthrough innovation projects with a market-creating potential” under the revamped SME instrument, which has been rolled out as part of the European Innovation Council (EIC) pilot. The SME Instrument supports high-risk, high-potential SMEs to develop and bring to market new products, services and business models that could drive economic growth.

The SME Instrument, which from 2018 has become an integral part of the European Innovation Council (EIC) Pilot, is an extremely competitive funding instrument, with an overall success rate of 8.4% for Phase 1 and 5.5% for Phase 2. Phase 1 aims at supporting the company in getting a grip on the R&D, technical feasibility and commercial potential of a ground-breaking, innovative idea and developing it into a credible business plan for scaling it up. Projects receive a lump sum of € 50,000 and last around 6 months. Phase 2 helps the companies in developing their business concept further into a market-ready product, service or process aligned with the growth strategy; projects, lasting 12 to 24 months, are funded between € 0.5 and € 2.5 million.

Braingineering Technologies (BTech), the “brainchild” of Professor Jens Schwamborn, is a young and innovative spin-off company from the Luxembourg Centre of Systems Biomedicine (LCSB), an interdisciplinary centre of the University of Luxembourg. BTech cultures human induced pluripotent stem cells (iPSCs) in a specific environment, thereby stimulating the development of so-called mini-brain organoids. These 3D structures, unlike traditional cell culture models, largely mimic the organisation and function of a real brain. Importantly, because these mini-brains can be cultured in arrays on microfluidic plates, they can be used for drug screening in a more cost and time efficient manner than would be possible with animal testing.

Furthermore, as iPSCs can nowadays be easily derived directly from a small biopsy (e.g. from Parkinson’s patients), the respective mini-brains carry exactly the same mutations as the patient, thus allowing for the development of truly personalised medicine. BTech uses their proprietary model to do pre-clinical drug testing and toxicology studies for pharmaceutical companies to identify new treatments for Parkinson’s disease. The support and coaching that BTech will receive through the first phase of the SME instrument will contribute to their consolidation and business development in the biotech sector.

Read more

How to write a competitive Horizon Europe proposal – starting level edition


On 27 June, the European R&D and Innovation team of Luxinnovation, represented by Rebecca Damotte, Stefano Pozzi Mucelli and Francois Sprumont, organised a Horizon Europe proposal writing workshop.
Read more

Listen to our podcast “Avec l'Europe pour horizon“


The Lëtzebuerger Journal podcast, with Rebecca Damotte and Charles Betz from Luxinnovation's European R&D and Innovation Support team, looks at the different programmes under Horizon Europe and how to participate as a Luxembourg entity.
Read more

Horizon Europe – focus on communication, dissemination and exploitation


Luxinnovation organised a one-hour webinar focusing on communication, dissemination and exploitation in Horizon Europe proposals.
Read more

Call to all Cluster 1 and Cluster 6 coordinators writing a two-stage proposal


Bridge2HE is organising Full Proposal Check events for Cluster 1 and Cluster 6 second-stage proposals with a deadline in September 2022. The events will take place online, in the week between 25 & 29 July 2022.
Read more

Differdange on the way to climate neutrality


With the support of Luxinnovation, the country's third largest city is participating in the European project to become climate neutral and intelligent.
Read more

Resources all news